Kalium Carbonicum Plex

Asafoetida, Carbo Vegetabilis, Cinchona Succirubra, Kali Carbonicum, Lycopodium Clavatum, Nux Moschata, Nux Vomica, Raphanus Sativus Var Niger


Seroyal Usa
Human Otc Drug
NDC 62106-1202
Kalium Carbonicum Plex also known as Asafoetida, Carbo Vegetabilis, Cinchona Succirubra, Kali Carbonicum, Lycopodium Clavatum, Nux Moschata, Nux Vomica, Raphanus Sativus Var Niger is a human otc drug labeled by 'Seroyal Usa'. National Drug Code (NDC) number for Kalium Carbonicum Plex is 62106-1202. This drug is available in dosage form of Liquid. The names of the active, medicinal ingredients in Kalium Carbonicum Plex drug includes Activated Charcoal - 6 [hp_X]/30mL Asafetida - 6 [hp_X]/30mL Cinchona Pubescens Bark - 6 [hp_X]/30mL Lycopodium Clavatum Spore - 6 [hp_X]/30mL Nutmeg - 6 [hp_X]/30mL Potassium Carbonate - 6 [hp_X]/30mL Raphanus Sativus - 6 [hp_X]/30mL Strychnos Nux-vomica Seed - 6 [hp_X]/30mL . The currest status of Kalium Carbonicum Plex drug is Active.

Drug Information:

Drug NDC: 62106-1202
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Kalium Carbonicum Plex
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Asafoetida, Carbo Vegetabilis, Cinchona Succirubra, Kali Carbonicum, Lycopodium Clavatum, Nux Moschata, Nux Vomica, Raphanus Sativus Var Niger
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Seroyal Usa
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Liquid
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ACTIVATED CHARCOAL - 6 [hp_X]/30mL
ASAFETIDA - 6 [hp_X]/30mL
CINCHONA PUBESCENS BARK - 6 [hp_X]/30mL
LYCOPODIUM CLAVATUM SPORE - 6 [hp_X]/30mL
NUTMEG - 6 [hp_X]/30mL
POTASSIUM CARBONATE - 6 [hp_X]/30mL
RAPHANUS SATIVUS - 6 [hp_X]/30mL
STRYCHNOS NUX-VOMICA SEED - 6 [hp_X]/30mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:SUBLINGUAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 16 Dec, 2015
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 24 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Seroyal USA
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000185371
N0000185375
N0000175629
N0000184306
M0000728
M0016962
M0006342
M0008672
M0516536
N0000185001
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:2P3VWU3H10
W9FZA51AS1
S96N10R972
C88X29Y479
AEE24M3MQ9
BQN1B9B9HA
86R5J6D01D
269XH13919
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Increased IgG Production [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Allergens [CS]
Plant Proteins [CS]
Dietary Proteins [CS]
Food Additives [CS]
Seed Storage Proteins [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Dietary Proteins [CS]
Food Additives [CS]
Increased Histamine Release [PE]
Increased IgG Production [PE]
Non-Standardized Food Allergenic Extract [EPC]
Non-Standardized Plant Allergenic Extract [EPC]
Plant Proteins [CS]
Seed Storage Proteins [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
62106-1202-01 BOTTLE, GLASS in 1 CARTON (62106-1202-0) / 30 mL in 1 BOTTLE, GLASS16 Dec, 2015N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Uses for the temporary relief of symptoms associated with digestive upset such as: bloating indigestion colic

Product Elements:

Kalium carbonicum plex asafoetida, carbo vegetabilis, cinchona succirubra, kali carbonicum, lycopodium clavatum, nux moschata, nux vomica, raphanus sativus var niger asafetida asafetida activated charcoal activated charcoal cinchona pubescens bark cinchona pubescens bark nutmeg nutmeg alcohol potassium carbonate carbonate ion lycopodium clavatum spore lycopodium clavatum spore strychnos nux-vomica seed strychnos nux-vomica seed raphanus sativus raphanus sativus water

Indications and Usage:

Uses for the temporary relief of symptoms associated with digestive upset such as: bloating indigestion colic directions to be taken ten minutes away from food. invert bottle and shake lightly allowing drops to fall directly under the tongue or into ¼ oz of water. hold contents for about 20 seconds and swallow. to promote drop flow, invert bottle and shake before each use. dosage frequency may be increased up to six times daily depending on the severity of symptoms. adults and adolescents (12 years and older) take 10 drops three times daily or as recommended by your healthcare practitioner. children (under 12 years) take under the direction of your healthcare practitioner.

Warnings:

Warnings stop use and ask a doctor if symptoms persist or worsen. if pregnant or breastfeeding, ask a health professional before use. keep out of reach of children. in case of overdose, get medical help or contact a poison control center right away.

Dosage and Administration:

Directions to be taken ten minutes away from food. invert bottle and shake lightly allowing drops to fall directly under the tongue or into ¼ oz of water. hold contents for about 20 seconds and swallow. to promote drop flow, invert bottle and shake before each use. dosage frequency may be increased up to six times daily depending on the severity of symptoms. adults and adolescents (12 years and older) take 10 drops three times daily or as recommended by your healthcare practitioner. children (under 12 years) take under the direction of your healthcare practitioner.

Stop Use:

Stop use and ask a doctor if symptoms persist or worsen.

Overdosage:

In case of overdose, get medical help or contact a poison control center right away.

Package Label Principal Display Panel:

Ndc 62106-1202-0 unda plex kalium carbonicum plex homeopathic preparation for the temporary relief of symptoms associated with digestive upset. contains 70% alcohol 1 fl oz (30 ml) 62106-1202


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.